RecruitingPhase 2NCT07680764

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)


Sponsor

Bristol-Myers Squibb

Enrollment

160 participants

Start Date

Aug 15, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Imzokitug and a drug called Pumitamig for people with locally advanced non-small cell lung cancer (nsclc) and metastatic non-small cell lung cancer (nsclc). The study is currently recruiting participants at 71 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPumitamig

Specified dose on specified days

DRUGImzokitug

Specified dose on specified days


Locations(71)

Local Institution - 0170

Athens, Georgia, United States

Local Institution - 0034

Lexington, Kentucky, United States

Local Institution - 0171

Lexington, Kentucky, United States

Local Institution - 0123

Baltimore, Maryland, United States

Local Institution - 0180

Hattiesburg, Mississippi, United States

Nebraska Cancer Specialists

Grand Island, Nebraska, United States

Oncology Hematology West PC

Omaha, Nebraska, United States

Local Institution - 0080

New York, New York, United States

Local Institution - 0105

Nashville, Tennessee, United States

Local Institution - 0095

Houston, Texas, United States

Local Institution - 0135

Madison, Wisconsin, United States

Local Institution - 0092

Viedma, Río Negro Province, Argentina

Local Institution - 0082

Rosario, Santa Fe Province, Argentina

Local Institution - 0094

Buenos Aires, Argentina

Local Institution - 0074

Gosford, New South Wales, Australia

Local Institution - 0134

Westmead, New South Wales, Australia

Local Institution - 0167

Greenslopes, Queensland, Australia

Local Institution - 0100

Heidelberg, Victoria, Australia

Local Institution - 0048

Perth, Western Australia, Australia

Local Institution - 0003

Natal/RN, Rio Grande do Norte, Brazil

Local Institution - 0006

Porto Alegre, Rio Grande do Sul, Brazil

Local Institution - 0005

Barretos, São Paulo, Brazil

Local Institution - 0001

São Paulo, Brazil

Local Institution - 0081

Santiago, Santiago Metropolitan, Chile

Local Institution - 0149

Santiago, Santiago Metropolitan, Chile

Local Institution - 0084

Viña del Mar, Valparaiso, Chile

Local Institution - 0038

Beijing, Beijing Municipality, China

Local Institution - 0138

Fuzhou, Fujian, China

Local Institution - 0050

Wuhan, Hubei, China

Local Institution - 0147

Nanjing, Jiangsu, China

Local Institution - 0140

Shanghai, Shanghai Municipality, China

Local Institution - 0169

Shanghai, Shanghai Municipality, China

Local Institution - 0144

Chengdu, Sichuan, China

Local Institution - 0137

Hangzhou, Zhejiang, China

Local Institution - 0131

Nice, Alpes-Maritimes, France

Local Institution - 0110

Marseille, Bouches-du-Rhône, France

Local Institution - 0087

Montpellier, Languedoc-Roussillon, France

Local Institution - 0119

Villejuif, Val-de-Marne, France

Local Institution - 0047

Grenoble, France

Local Institution - 0109

Paris, France

Local Institution - 0085

Saint-Herblain, France

Local Institution - 0019

Paris, Île-de-France Region, France

Local Institution - 0126

Stuttgart, Baden-Wurttemberg, Germany

Local Institution - 0156

Marburg, Hesse, Germany

Local Institution - 0152

Homburg, Saarland, Germany

Local Institution - 0065

Cologne, Germany

Local Institution - 0042

Haile, Germany

Local Institution - 0125

Hessen, Germany

Local Institution - 0128

Misterbianco, Catania, Italy

Local Institution - 0043

Bari, Italy

Local Institution - 0148

Bergamo, Italy

Local Institution - 0159

Milan, Italy

Local Institution - 0014

Ravenna, Italy

Local Institution - 0011

Rozzano (MI), Italy

Local Institution - 0114

Florești, Cluj, Romania

Local Institution - 0113

Timișoara, Timiș County, Romania

Local Institution - 0076

Bucharest, Romania

Local Institution - 0008

Cluj-Napoca, Romania

Local Institution - 0075

Craiova, Romania

Local Institution - 0115

Iași, Romania

Local Institution - 0116

Iași, Romania

Local Institution - 0132

Badalona, Barcelona, Spain

Local Institution - 0162

Seville, Seville, Spain

Local Institution - 0027

Barcelona, Spain

Local Institution - 0068

Barcelona, Spain

Local Institution - 0163

Barcelona, Spain

Local Institution - 0041

Madrid, Spain

Local Institution - 0010

Majadahonda, Spain

Local Institution - 0020

Málaga, Spain

Local Institution - 0035

London, Greater London, United Kingdom

Local Institution - 0037

Guildford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07680764


Related Trials